Expert Financial Analysis and Reporting

Summary and Overview Curis has demonstrated impressive drug development capability in the oncology space. However, it has followed a policy of licensing drugs early in development and passing development costs and risks on to the licensor. This de-risked the drug development for Curis, but at the cost of giving up significant economics. For example, its […]

I continue to recommend purchase of Cadence based on trends seen in the 1Q, 2011 period. The details of my recommendation are outlined in my report of March 13, 2011.   Overview and Stock Opinion I believe that Ofirmev meets a major unmet need for an alternative to narcotics and NSAIDs in the intravenous analgesic […]

I am recommending purchase of Cadence Pharmaceuticals based on the promise of its recently launched intravenous analgesic, Ofirmev. Stock Opinion Cadence Pharmaceuticals achieved the dream of every emerging bio-pharmaceutical company when it received US approval for its first product Ofirmev on November 2, 2010; it was then launched on January 17, 2011. Ofirmev is an […]

The PDUFA date for ipilimumab is coming up on March 26th. This is an important component of BMY’s outstanding pipeline. I anticipate approval.   Ipilimumab is Up on the News Front- Will It Be Approved on Its March 26 PDUFA Date? I wrote that I believe that Bristol-Myers Squibb has an outstanding pipeline in my […]

I was expecting approval of ipilimumab for patients who had failed prior therapy. I was surprised that the FDA also approved it for treatment naive patients. The price of $120,000 for a course of therapy exceeded my projection of $50,000 to $60,000.   Key Points The FDA approval of Bristol-Myers Squibb’s new oncology drug Yervoy […]

I think that Bristol-Myers Squibb has one of the most attractive drug pipelines of the big pharma companies. Although it faces a steep patent cliff that by my projections will results in a sales decline until 2014, the stock is attractive because of the highly promising drug pipeline and the dividend yield of 5.2%. I […]

Pfizer is entering a patent cliff period in which sales will decline over the next two years. The drug pipleline is modestly promising but not so much so that it can significantly accelerate the giant sales base of the company in ensuing years. The current dividend yield of 4.1% and a strong cash flow that […]

I met with Anadys’ CEO Steve Worland and IR contact Amy Conrad at their offices in San Diego for an update on ANA 598. Company Update: Anadys’ lead compound is ANA598, a small molecule non-nucleoside inhibitor of HCV RNA polymerase. To date, ANDS has completed one phase I study in healthy volunteers. A second phase […]

Entereg Results in the Quarter Were Excellent Entereg achieved sales of $7.5 million which was an increase of 41% from 1Q, 2010 and a slight sequential increase from the $7.3 million of 4Q, 2010. The company reported that the Entereg business is now operating at an annual run rate of $30 million, a level at […]

Adolor as a Stock While I am currently neutral on Adolor, it is a stock that I am watching closely. To become more positive, I need to gain more confidence that their lead drug Entereg, which has had a slower than expected sales ramp up since its introduction in 3Q, 2008 can grow from a […]